Xenetic Biosciences (NASDAQ:XBIO) Releases Quarterly Earnings Results

Xenetic Biosciences (NASDAQ:XBIO) released its quarterly earnings results on Tuesday. The company reported ($0.20) EPS for the quarter, FiscalAI reports. The business had revenue of $0.81 million for the quarter. Xenetic Biosciences had a negative return on equity of 51.27% and a negative net margin of 90.09%.

Xenetic Biosciences Stock Down 3.8%

XBIO stock opened at $3.02 on Wednesday. The business’s fifty day moving average is $2.97 and its 200-day moving average is $2.64. The company has a market cap of $6.92 million, a P/E ratio of -1.90 and a beta of 2.20. Xenetic Biosciences has a twelve month low of $1.90 and a twelve month high of $13.93.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Xenetic Biosciences in a research report on Monday, April 20th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Xenetic Biosciences stock. Renaissance Technologies LLC grew its stake in Xenetic Biosciences, Inc. (NASDAQ:XBIO) by 516.6% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 178,509 shares of the company’s stock after purchasing an additional 149,559 shares during the quarter. Renaissance Technologies LLC owned about 7.80% of Xenetic Biosciences worth $387,000 at the end of the most recent reporting period. 15.12% of the stock is currently owned by institutional investors.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.